Graft Failure Clinical Trial
Official title:
PATency assessmENt of Grafts by Computerized tomographY in CORONARY Patients: the PATENCY-CORONARY Trial
Heart bypass surgery is used to increase blood flow to the heart. This surgery is usually done using a heart-lung machine (on-pump surgery) allowing the surgeon to perform the procedure on a still heart. However, this heart-lung machine causes an inflammatory response and is linked with complications such as heart injury, stroke, brain injury, kidney failure, need for blood transfusions, irregular heart rhythms and death. An effective way of counteracting the effects of the heart-lung machine is to not use the pump itself, thus performing the bypass surgery with a beating heart (off-pump surgery). However, off-pump surgery is technically more difficult, possibly associated with a decrease in graft patency. The ongoing Coronary Artery Bypass Graft Off or On Pump Revascularization Study (CORONARY), is a prospective randomized clinical trial comparing bypass surgery done with and without the pump. Worldwide, 4700 patients will be included and followed up for 5 years. The proposed research project, The Patency AssessmenT of grafts pErformed iN CORONARY (PATENCY-CORONARY), is a prospective clinical trial for the evaluation of patency (or "openness") of the bypass grafts that will enrol 1200 consecutive CORONARY patients reaching their one year follow-up. Patients will undergo a non-invasive scan using X-rays to safely and quickly evaluate graft patency. The PATENCY-CORONARY trial will determine if off-pump surgery is associated with decreased graft patency at 1-year post-surgery compared to on-pump surgery when performed by skilled surgeons in different clinical settings, whether decreased graft patency is associated with adverse short and long-term outcomes, and explore other risk factors associated with decreased graft patency.
Background: As Coronary Artery Bypass Grafting (CABG) aims to restore adequate blood supply
to the ischemic heart, the success of the operation should depend mainly on the patency of
the bypass grafts. Graft failure has consequences similar to those of native coronary artery
disease: recurrent angina, myocardial infarct (MI), additional revascularization procedures,
and premature death. CABG is generally performed using cardiopulmonary bypass (CPB) with
cardioplegic arrest allowing the surgeon to complete the delicate coronary anastomoses on a
still heart in a bloodless field. Off-pump CABG surgery using specially designed heart
stabilizer systems has been proposed as a less invasive approach to CABG avoiding the CPB
circuit itself. The benefits of off-pump CABG compared with conventional on-pump CABG are
still intensively debated. Multislice spiral computed tomography angiography (CTA) represents
a non-invasive method as compared to conventional coronary angiography allowing a
comprehensive and objective imaging of bypass grafts and native coronaries with elevated
diagnostic accuracy.
Rationale: CORONARY trial (NCT00463294) is a large, international, prospective, CIHR-funded,
randomized controlled trial assessing both the short and long-term clinical outcomes of 4,700
patients undergoing on-pump or off-pump CABG. However, angiographic evaluation of coronary
graft patency was not intended in CORONARY.
Objectives: PATENCY-CORONARY is a new prospective trial of a consecutive subset of 1,200
CORONARY patients reaching their one-year follow-up who will undergo graft patency assessment
using CTA and 3D reconstructions. This trial will determine whether off-pump compared to
on-pump CABG surgery is associated with lower CABG patency when performed by experienced
surgeons and if there is an association between graft failure assessed by CTA, and the
occurrence of CORONARY primary outcomes (composite of death, angina, MI, stroke, renal
failure and new coronary revascularization [CABG or PCI]).
Primary outcome: CABG patency index (i.e. the percentage of patent [non-occluded] distal
anastomoses out of the total number of distal anastomoses for all patients) at 1 year after
CABG surgery by experienced surgeons; Secondary outcomes: 1) graft lesion severity on a
3-point scale at 1 year (mimicking the FitzGibbon grading ABO); and 2) percentage of patients
with at least one occluded bypass graft at 1 year; Tertiary outcome: correlation between CTA
findings (compromised grafts) with CORONARY primary outcomes(composite of death, angina, MI,
stroke, renal failure and new coronary revascularization [CABG or PCI]), at one and five-year
of follow-up post-CABG.
Methods: All CORONARY patients reaching their one-year follow-up will be included
consecutively in the PATENCY-CORONARY trial until the target of 1,200 CTA is reached and
reasons for exclusion will be noted prospectively to prevent selection bias. Amount of
contrast agent used, radiation dose and potential morbidities during this imaging procedure
will be recorded. Each CTA examination will be assessed by two experienced and blinded
radiologists and each graft will be classified according to conduit type and portions: body
of the graft, anastomoses and the distal native coronary bed. In addition of PATENCY-CORONARY
outcome analyses, patients undergoing CTA will be compared to excluded patients (no CTA) and
the overall cohort of patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT03663036 -
Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis
|
N/A | |
Not yet recruiting |
NCT05855707 -
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
|
Phase 1 | |
Recruiting |
NCT04967391 -
Tumescence in HNC Skin Graft Reconstruction
|
Phase 3 | |
Recruiting |
NCT02061462 -
EVLP to Evaluate the Eligibility for Transplantation of DCD-Lungs
|
Phase 1 | |
Completed |
NCT01970605 -
Silver Graft All Comers Registry
|
||
Terminated |
NCT01564095 -
TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
|
Phase 2/Phase 3 | |
Terminated |
NCT00208884 -
Terminal Graft Failure
|
N/A | |
Recruiting |
NCT04779957 -
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy
|
Phase 2 | |
Terminated |
NCT04494061 -
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
|
||
Terminated |
NCT04731298 -
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
|
Phase 2 | |
Completed |
NCT01848249 -
Deceased Donor Biomarkers and Recipient Outcomes
|
||
Active, not recruiting |
NCT02556879 -
Immunization Anti HLA in the Liver Transplant Recipients (DSATH)
|
N/A | |
No longer available |
NCT02026934 -
CliniMACS® CD34+ Reagent System for Expanded Access Use
|
N/A | |
Recruiting |
NCT00472329 -
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT04542954 -
Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
|
||
Recruiting |
NCT03717545 -
Second Transplantation for Graft Failure
|
N/A | |
Recruiting |
NCT03019809 -
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
|
Phase 2 | |
Recruiting |
NCT01631058 -
Renal Transplantation in the Elderly - nEverOld Study
|
Phase 4 | |
Completed |
NCT06340607 -
Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients
|